<DOC>
	<DOCNO>NCT00717652</DOCNO>
	<brief_summary>The objective study evaluate clinical activity association ( tretinoin + arbutin + triamcinolone ) treatment epidermal melasma .</brief_summary>
	<brief_title>Efficiency And Safety Of Association Arbutin , Triamcinolone And Tretinoin In Treatment Of Melasma</brief_title>
	<detailed_description>The melasma common hipermelanosis , acquire , symmetrical , irregular occur area photo-exposed face , forehead temple , affect eyelid tion . The facial region affect : zigomatic ( 82.4 % ) , parotid ( 64.7 % ) , front ( 64.7 % ) , mandible ( 35.3 % ) nasal ( 35.3 % ) . The injury melasma variable increase epidermal melanin inflammatory infiltrate mild moderate intensity . Treatment compound hydroquinone derivative , tretinoin , corticosteroid moderate combination show good result , diminish training , reduce stability promote destruction melanocyte . The primary objective study evaluate clinical activity association ( tretinoin + arbutin + triamcinolone ) manufacture Glenmark Laboratory , comparator drug product Triluma ® ( hydroquinone + fluocinolone + tretinoin ) , treatment epidermal melasma parameter clinical course disease ( improves ) security . Patients include study randomly automatically receive one treatment ( New association Triluma ® ) , use 12 week . The product apply region affect day , night . The evaluation clinical improvement , well security , hold periodic visit , describe , hold record supply medicine patient . In visit , beyond clinical examination photograph large , filled Area Severity Scale ( Melasma Area Severity Index - MASI ) , quantify melasma main tool control clinical improvement . At end study , data compare , show inferiority inferiority clinical drug test relation comparator .</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Women adult age 18 year ; Patients suffer melasma Epidermal face mild moderate ; Patients do treatment melasma 3 month precede study ; Patients good mental physical health ; Patients agree purpose study sign TCLE . Patients skin disease melasma , interfere clinical evaluation hemangioma queloides ; Patients melasma skin mixed ; Patients sensitivity agent hipopigmentantes ; Patients sensitivity fotoprotetores ; Patients pregnant breastfeeding ; Patients , discretion doctor , able participate study ; Patients carry treatment melasma 3 month precede study Patients agree term describe Statement Informed Consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>